{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:44:12Z","timestamp":1790113452678,"version":"4.0.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>With the approvals of various targeted therapies including tyrosine kinase inhibitors to antibody\u2013drug conjugates, the treatment landscape of patients with EGFR-mutant non-small cell lung cancer has drastically improved. The use of EGFR-targeted therapies has shifted to include not only advanced\/ metastatic disease but also to early-stage non-small cell lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Novel therapy options have sought to address the need for effective agents against acquired resistance mechanisms in EGFR mutations. Further, the role of tyrosine kinase inhibitors against EGFR mutation in the perioperative setting has been most recently evaluated. With early outcomes, clinicians are met with the need to guide patients through various treatment regimens, and mature survival results are anticipated for several key trials. Of import, the growing focus on personalized treatment options based on outcomes, quality-of-life, toxicity, tolerability, and various disease-related factors warrants consideration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review comprehensively describes frontline and subsequent-line therapy options for patients with early stage, unresectable\/ locally advanced, and advanced\/ metastatic stages of EGFR-mutant non-small cell lung cancer, including unprecedented therapeutic agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11912-026-01751-0","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T10:24:14Z","timestamp":1775903054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC)"],"prefix":"10.1007","volume":"28","author":[{"given":"Abhinav","family":"Vyas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Jin","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanad","family":"Alhushki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Singhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawzi Abu","family":"Rous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5378-9434","authenticated-orcid":false,"given":"Rajat","family":"Thawani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2943-3817","authenticated-orcid":false,"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"21","key":"1751_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129\u201339. https:\/\/doi.org\/10.1056\/NEJMoa040938.","journal-title":"N Engl J Med"},{"issue":"10","key":"1751_CR2","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa0904554","volume":"361","author":"R Rosell","year":"2009","unstructured":"Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958\u201367. https:\/\/doi.org\/10.1056\/NEJMoa0904554.","journal-title":"N Engl J Med"},{"issue":"9","key":"1751_CR3","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243\u201360. https:\/\/doi.org\/10.1097\/JTO.0000000000000630.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"1751_CR4","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/s0959-8049(96)00243-2","volume":"32A","author":"S Fujino","year":"1996","unstructured":"Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer. 1996;32A(12):2070\u20134. https:\/\/doi.org\/10.1016\/s0959-8049(96)00243-2.","journal-title":"Eur J Cancer"},{"issue":"2 Suppl","key":"1751_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijrobp.2003.11.041","volume":"59","author":"RS Herbst","year":"2004","unstructured":"Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21\u20136. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.11.041.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1 Suppl 4","key":"1751_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1053\/sonc.2002.31520","volume":"29","author":"WA Franklin","year":"2002","unstructured":"Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002;29(1 Suppl 4):3\u201314. https:\/\/doi.org\/10.1053\/sonc.2002.31520.","journal-title":"Semin Oncol"},{"issue":"7","key":"1751_CR7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","volume":"19","author":"M Borgeaud","year":"2024","unstructured":"Borgeaud M, Parikh K, Banna GL, et al. Unveiling the landscape of uncommon EGFR mutations in NSCLC-a systematic review. J Thorac Oncol. 2024;19(7):973\u201383. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.016.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1751_CR8","first-page":"1133","volume":"13","author":"K Pavelic","year":"1993","unstructured":"Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 1993;13(4):1133\u20137.","journal-title":"Anticancer Res"},{"issue":"1","key":"1751_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/bjc.1993.306","volume":"68","author":"D Veale","year":"1993","unstructured":"Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer. 1993;68(1):162\u20135. https:\/\/doi.org\/10.1038\/bjc.1993.306.","journal-title":"Br J Cancer"},{"issue":"4","key":"1751_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/bjc.1998.106","volume":"77","author":"M Volm","year":"1998","unstructured":"Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer. 1998;77(4):663\u20139. https:\/\/doi.org\/10.1038\/bjc.1998.106.","journal-title":"Br J Cancer"},{"issue":"2","key":"1751_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"issue":"10","key":"1751_CR12","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jtho.2024.06.008","volume":"19","author":"RA Soo","year":"2024","unstructured":"Soo RA, Reungwetwattana T, Perroud HA, et al. Prevalence of EGFR mutations in patients with resected stages I to III NSCLC: Results from the EARLY-EGFR Study. J Thorac Oncol. 2024;19(10):1449\u201359. https:\/\/doi.org\/10.1016\/j.jtho.2024.06.008.","journal-title":"J Thorac Oncol"},{"issue":"25","key":"1751_CR13","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1200\/JCO.19.00075","volume":"37","author":"WZ Zhong","year":"2019","unstructured":"Zhong WZ, Chen KN, Chen C, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol. 2019;37(25):2235\u201345. https:\/\/doi.org\/10.1200\/JCO.19.00075.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1751_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","volume":"16","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, He Y, Li W, et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study. Target Oncol. 2021;16(2):165\u201376. https:\/\/doi.org\/10.1007\/s11523-021-00794-6.","journal-title":"Target Oncol"},{"issue":"26","key":"1751_CR15","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1200\/JCO.23.00515","volume":"41","author":"BC Cho","year":"2023","unstructured":"Cho BC, Ahn MJ, Kang JH, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301. J Clin Oncol. 2023;41(26):4208\u201317. https:\/\/doi.org\/10.1200\/JCO.23.00515.","journal-title":"J Clin Oncol"},{"key":"1751_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.lungcan.2018.10.027","volume":"126","author":"T John","year":"2018","unstructured":"John T, Akamatsu H, Delmonte A, et al. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. Lung Cancer. 2018;126:133\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.027.","journal-title":"Lung Cancer"},{"issue":"9","key":"1751_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S2213-2600(18)30264-9","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Cheng Y, An T, et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir Med. 2018;6(9):681\u201390. https:\/\/doi.org\/10.1016\/S2213-2600(18)30264-9.","journal-title":"Lancet Respir Med"},{"key":"1751_CR18","unstructured":"MA15.11 Real world biomarker testing and treatment patterns in patients with advanced NSCLC Receiving EGFR-TKIs - Journal of Thoracic Oncology. Accessed July 25, 2025. https:\/\/www.jto.org\/article\/S1556-0864(18)31405-9\/fulltext."},{"issue":"1","key":"1751_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"issue":"5","key":"1751_CR20","doi-asserted-by":"publisher","first-page":"100271","DOI":"10.1016\/j.esmoop.2021.100271","volume":"6","author":"D Planchard","year":"2021","unstructured":"Planchard D, Feng PH, Karaseva N, et al. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced\/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. ESMO Open. 2021;6(5):100271. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100271.","journal-title":"ESMO Open"},{"issue":"21","key":"1751_CR21","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2306434.","journal-title":"N Engl J Med"},{"issue":"4","key":"1751_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.24.00533","volume":"43","author":"X Le","year":"2025","unstructured":"Le X, Patel JD, Shum E, et al. A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial). J Clin Oncol. 2025;43(4):403\u201311. https:\/\/doi.org\/10.1200\/JCO.24.00533.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1751_CR23","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","volume":"393","author":"JCH Yang","year":"2025","unstructured":"Yang JCH, Lu S, Hayashi H, et al. Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2025;393(17):1681\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2503001.","journal-title":"N Engl J Med"},{"issue":"6","key":"1751_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2217\/fon-2021-0923","volume":"18","author":"BC Cho","year":"2022","unstructured":"Cho BC, Felip E, Hayashi H, et al. Mariposa: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022;18(6):639\u201347. https:\/\/doi.org\/10.2217\/fon-2021-0923.","journal-title":"Future Oncol"},{"issue":"27","key":"1751_CR25","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu S, Dong X, Jian H, et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J Clin Oncol. 2022;40(27):3162\u201371. https:\/\/doi.org\/10.1200\/JCO.21.02641.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1751_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jtho.2022.01.015","volume":"17","author":"Y Shi","year":"2022","unstructured":"Shi Y, Zhao Y, Yang S, et al. Safety, efficacy, and pharmacokinetics of rezivertinib (BPI-7711) in patients with advanced NSCLC with EGFR T790M mutation: a phase 1 dose-escalation and dose-expansion study. J Thorac Oncol. 2022;17(5):708\u201317. https:\/\/doi.org\/10.1016\/j.jtho.2022.01.015.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"1751_CR27","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jtho.2018.03.025","volume":"13","author":"Y Ma","year":"2018","unstructured":"Ma Y, Zheng X, Zhao H, et al. First-in-human phase i study of AC0010, a mutant-selective EGFR inhibitor in non-small cell lung cancer: safety, efficacy, and potential mechanism of resistance. J Thorac Oncol. 2018;13(7):968\u201377. https:\/\/doi.org\/10.1016\/j.jtho.2018.03.025.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"1751_CR28","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0281","volume":"15","author":"X Xu","year":"2016","unstructured":"Xu X, Mao L, Xu W, et al. AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients. Mol Cancer Ther. 2016;15(11):2586\u201397. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0281.","journal-title":"Mol Cancer Ther"},{"key":"1751_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejca.2021.02.019","volume":"149","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Asahina H, Kishimoto J, et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial. Eur J Cancer. 2021;149:14\u201322. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.019.","journal-title":"Eur J Cancer"},{"issue":"12","key":"1751_CR30","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 Cancer Groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749\u201368. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2996.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1751_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Wspolczesna Onkol. 2021;25(1):45\u201352. https:\/\/doi.org\/10.5114\/wo.2021.103829.","journal-title":"Wspolczesna Onkol"},{"issue":"36","key":"1751_CR32","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306\u201311. https:\/\/doi.org\/10.1073\/pnas.0405220101.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10299","key":"1751_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(21)00312-3.","journal-title":"Lancet"},{"issue":"2","key":"1751_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cllc.2020.09.023","volume":"22","author":"H Asahina","year":"2021","unstructured":"Asahina H, Tanaka K, Morita S, et al. A phase II study of Osimertinib combined with platinum plus Pemetrexed in patients with EGFR-mutated advanced non-small-cell lung cancer: the OPAL study (NEJ032C\/LOGIK1801). Clin Lung Cancer. 2021;22(2):147\u201351. https:\/\/doi.org\/10.1016\/j.cllc.2020.09.023.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"1751_CR35","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/cancers16050940","volume":"16","author":"A Desai","year":"2024","unstructured":"Desai A, V\u00e1zquez TA, Arce KM, et al. ctDNA for the evaluation and management of EGFR-mutant non-small cell lung cancer. Cancers (Basel). 2024;16(5):940. https:\/\/doi.org\/10.3390\/cancers16050940.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1751_CR36","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","volume":"16","author":"JCH Yang","year":"2015","unstructured":"Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(15)00026-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1751_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamaoncol.2023.5013","volume":"10","author":"Y Okuma","year":"2024","unstructured":"Okuma Y, Kubota K, Shimokawa M, et al. First-line Osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial. JAMA Oncol. 2024;10(1):43\u201351. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5013.","journal-title":"JAMA Oncol"},{"key":"1751_CR38","doi-asserted-by":"publisher","first-page":"107926","DOI":"10.1016\/j.lungcan.2024.107926","volume":"195","author":"A Barsouk","year":"2024","unstructured":"Barsouk A, Elghawy O, Heidlauf A, et al. Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) treated with osimertinib (osi) vs. afatinib or erlotinib. Lung Cancer. 2024;195:107926. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107926.","journal-title":"Lung Cancer"},{"issue":"1","key":"1751_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.117.","journal-title":"Ann Oncol"},{"key":"1751_CR40","doi-asserted-by":"publisher","first-page":"S1244","DOI":"10.1016\/j.annonc.2024.08.2296","volume":"35","author":"S Popat","year":"2024","unstructured":"Popat S, Reckamp KL, Califano R, et al. LBA54 amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: second interim overall survival from MARIPOSA-2. Ann Oncol. 2024;35:S1244\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2296.","journal-title":"Ann Oncol"},{"issue":"3","key":"1751_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S2213-2600(23)00379-X","volume":"12","author":"M Wang","year":"2024","unstructured":"Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2024;12(3):217\u201324. https:\/\/doi.org\/10.1016\/S2213-2600(23)00379-X.","journal-title":"Lancet Respir Med"},{"key":"1751_CR42","doi-asserted-by":"publisher","first-page":"S755","DOI":"10.1016\/j.annonc.2023.09.2348","volume":"34","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Ahn MJ, Lisberg AE, et al. 1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs). Ann Oncol. 2023;34:S755\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2348.","journal-title":"Ann Oncol"},{"key":"1751_CR43","doi-asserted-by":"publisher","unstructured":"Datopotamab Deruxtecan in Advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations: Results from the Phase II TROPION-Lung05 Study | Journal of Clinical Oncology. Accessed July 25, 2025https:\/\/doi.org\/10.1200\/JCO-24-01349.","DOI":"10.1200\/JCO-24-01349"},{"issue":"35","key":"1751_CR44","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/JCO.23.01476","volume":"41","author":"HA Yu","year":"2023","unstructured":"Yu HA, Goto Y, Hayashi H, et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;41(35):5363\u201375. https:\/\/doi.org\/10.1200\/JCO.23.01476.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1751_CR45","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/jco.2025.43.16_suppl.8506","volume":"43","author":"TSK Mok","year":"2025","unstructured":"Mok TSK, Yu HA, Lim SM, et al. Patritumab deruxtecan (HER3-DXd) in resistant EGFR -mutated ( EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. JCO. 2025;43(16_suppl):8506\u20138506. https:\/\/doi.org\/10.1200\/jco.2025.43.16_suppl.8506.","journal-title":"JCO"},{"issue":"7","key":"1751_CR46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"W Fang","year":"2024","unstructured":"HARMONi-A Study Investigators, Fang W, Zhao Y, et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA. 2024;332(7):561\u201370. https:\/\/doi.org\/10.1001\/jama.2024.10613.","journal-title":"JAMA"},{"issue":"7","key":"1751_CR47","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1612674.","journal-title":"N Engl J Med"},{"issue":"7","key":"1751_CR48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391(7):585\u201397. https:\/\/doi.org\/10.1056\/NEJMoa2402614.","journal-title":"N Engl J Med"},{"issue":"6","key":"1751_CR49","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/thoraxjnl-2012-202297","volume":"68","author":"S Walters","year":"2013","unstructured":"Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004\u20132007. Thorax. 2013;68(6):551\u201364. https:\/\/doi.org\/10.1136\/thoraxjnl-2012-202297.","journal-title":"Thorax"},{"issue":"5","key":"1751_CR50","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/jrr\/rrw075","volume":"57","author":"S Ochiai","year":"2016","unstructured":"Ochiai S, Nomoto Y, Watanabe Y, et al. The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis. J Radiat Res. 2016;57(5):449\u201359. https:\/\/doi.org\/10.1093\/jrr\/rrw075.","journal-title":"J Radiat Res"},{"key":"1751_CR51","doi-asserted-by":"publisher","first-page":"175346661988553","DOI":"10.1177\/1753466619885530","volume":"13","author":"A Botticella","year":"2019","unstructured":"Botticella A, Mezquita L, Le Pechoux C, Planchard D. Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience. Ther Adv Respir Dis. 2019;13:1753466619885530. https:\/\/doi.org\/10.1177\/1753466619885530.","journal-title":"Ther Adv Respir Dis"},{"key":"1751_CR52","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3389\/fonc.2019.00877","volume":"9","author":"L Giuranno","year":"2019","unstructured":"Giuranno L, Ient J, De Ruysscher D, Vooijs MA. Radiation-induced lung injury (RILI). Front Oncol. 2019;9:877. https:\/\/doi.org\/10.3389\/fonc.2019.00877.","journal-title":"Front Oncol"},{"key":"1751_CR53","doi-asserted-by":"publisher","first-page":"1036334","DOI":"10.3389\/fphar.2022.1036334","volume":"13","author":"W Liu","year":"2022","unstructured":"Liu W, Ren S, Xiao Y, Yang L, Zeng C, Hu Y. Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: current status and future considerations. Front Pharmacol. 2022;13:1036334. https:\/\/doi.org\/10.3389\/fphar.2022.1036334.","journal-title":"Front Pharmacol"},{"key":"1751_CR54","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-015-0151-3","volume":"8","author":"W Zhong","year":"2015","unstructured":"Zhong W, Yang X, Yan H, et al. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. J Hematol Oncol. 2015;8:54. https:\/\/doi.org\/10.1186\/s13045-015-0151-3.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1751_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3760\/cma.j.issn.0253-3766.2018.02.010","volume":"40","author":"WQ Chen","year":"2018","unstructured":"Chen WQ, Li P, Wang Q, et al. A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage \u2162A EGFR-mutant lung adenocarcinoma. Zhonghua Zhong Liu Za Zhi. 2018;40(2):133\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2018.02.010.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"7","key":"1751_CR56","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/oncolo\/oyae107","volume":"29","author":"AEB Chang","year":"2024","unstructured":"Chang AEB, Piper-Vallillo AJ, Mak RH, et al. The ASCENT trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC. Oncologist. 2024;29(7):609\u201318. https:\/\/doi.org\/10.1093\/oncolo\/oyae107.","journal-title":"Oncologist"},{"issue":"26","key":"1751_CR57","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.24.00071","volume":"42","author":"CM Blakely","year":"2024","unstructured":"Blakely CM, Urisman A, Gubens MA, et al. Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study. J Clin Oncol. 2024;42(26):3105\u201314. https:\/\/doi.org\/10.1200\/JCO.24.00071.","journal-title":"J Clin Oncol"},{"key":"1751_CR58","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","volume":"178","author":"C Lv","year":"2023","unstructured":"Lv C, Fang W, Wu N, et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial. Lung Cancer. 2023;178:151\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2023.02.011.","journal-title":"Lung Cancer"},{"key":"1751_CR59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00883","author":"J He","year":"2025","unstructured":"He J, Tsuboi M, Weder W, et al. Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-25-00883.","journal-title":"J Clin Oncol"},{"issue":"27","key":"1751_CR60","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1200\/JCO.2013.51.1816","volume":"31","author":"GD Goss","year":"2013","unstructured":"Goss GD, O\u2019Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013;31(27):3320\u20136. https:\/\/doi.org\/10.1200\/JCO.2013.51.1816.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1751_CR61","doi-asserted-by":"publisher","first-page":"e0140794","DOI":"10.1371\/journal.pone.0140794","volume":"10","author":"S Feng","year":"2015","unstructured":"Feng S, Wang Y, Cai K, et al. Randomized adjuvant chemotherapy of EGFR-mutated non-small cell lung cancer patients with or without Icotinib consolidation therapy. PLoS One. 2015;10(10):e0140794. https:\/\/doi.org\/10.1371\/journal.pone.0140794.","journal-title":"PLoS One"},{"issue":"34","key":"1751_CR62","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","volume":"33","author":"K Kelly","year":"2015","unstructured":"Kelly K, Altorki NK, Eberhardt WEE, et al. Adjuvant Erlotinib versus placebo in patients with stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A randomized, double-blind. Phase III Trial J Clin Oncol. 2015;33(34):4007\u201314. https:\/\/doi.org\/10.1200\/JCO.2015.61.8918.","journal-title":"Phase III Trial J Clin Oncol"},{"issue":"3","key":"1751_CR63","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.21.01729","volume":"40","author":"H Tada","year":"2022","unstructured":"Tada H, Mitsudomi T, Misumi T, et al. Randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small-cell lung cancer with EGFR mutation (IMPACT). J Clin Oncol. 2022;40(3):231\u201341. https:\/\/doi.org\/10.1200\/JCO.21.01729.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1751_CR64","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1200\/JCO.22.00051","volume":"40","author":"K Pisters","year":"2022","unstructured":"Pisters K, Kris MG, Gaspar LE, Ismaila N. Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small-cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022;40(10):1127\u20139. https:\/\/doi.org\/10.1200\/JCO.22.00051.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1751_CR65","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1994.","journal-title":"Ann Oncol"},{"issue":"18","key":"1751_CR66","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2027071.","journal-title":"N Engl J Med"},{"issue":"10","key":"1751_CR67","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","volume":"41","author":"RS Herbst","year":"2023","unstructured":"Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023;41(10):1830\u201340. https:\/\/doi.org\/10.1200\/JCO.22.02186.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1751_CR68","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389(2):137\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2304594.","journal-title":"N Engl J Med"},{"key":"1751_CR69","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","volume":"45","author":"S Peters","year":"2016","unstructured":"Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139\u201362. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.009.","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"1751_CR70","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.13.9030.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1751_CR71","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169\u201381. https:\/\/doi.org\/10.1038\/nrc2088.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1751_CR72","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1097\/JTO.0000000000000516","volume":"10","author":"LM Sholl","year":"2015","unstructured":"Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience. J Thorac Oncol. 2015;10(5):768\u201377. https:\/\/doi.org\/10.1097\/JTO.0000000000000516.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1751_CR73","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","volume":"19","author":"WZ Zhong","year":"2018","unstructured":"Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1\u2013N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(17)30729-5.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1751_CR74","doi-asserted-by":"publisher","first-page":"15924","DOI":"10.18632\/oncotarget.12741","volume":"8","author":"A Levy","year":"2016","unstructured":"Levy A, Bardet E, Lacas B, et al. A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. Oncotarget. 2016;8(9):15924\u201333. https:\/\/doi.org\/10.18632\/oncotarget.12741.","journal-title":"Oncotarget"},{"issue":"17_suppl","key":"1751_CR75","doi-asserted-by":"publisher","first-page":"LBA4-LBA4","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4","volume":"42","author":"SS Ramalingam","year":"2024","unstructured":"Ramalingam SS, Kato T, Dong X, et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: primary results of the phase 3 LAURA study. JCO. 2024;42(17_suppl):LBA4\u2013LBA4. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA4.","journal-title":"JCO"},{"issue":"5","key":"1751_CR76","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","volume":"16","author":"M Nagasaka","year":"2021","unstructured":"Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou SHI. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol. 2021;16(5):740\u201363. https:\/\/doi.org\/10.1016\/j.jtho.2020.11.028.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1751_CR77","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/13696998.2017.1377718","volume":"21","author":"E Bertranou","year":"2018","unstructured":"Bertranou E, Bodnar C, Dansk V, Greystoke A, Large S, Dyer M. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. J Med Econ. 2018;21(2):113\u201321. https:\/\/doi.org\/10.1080\/13696998.2017.1377718.","journal-title":"J Med Econ"},{"issue":"2","key":"1751_CR78","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jtho.2017.10.012","volume":"13","author":"B Wu","year":"2018","unstructured":"Wu B, Gu X, Zhang Q. Cost-effectiveness of osimertinib for EGFR mutation-positive non-small cell lung cancer after progression following first-line EGFR TKI therapy. J Thorac Oncol. 2018;13(2):184\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2017.10.012.","journal-title":"J Thorac Oncol"},{"key":"1751_CR79","unstructured":"ESMO 2017: Osimertinib in Asia-Pacific patients (pts) with EGFR T790M-positive advanced NSCLC: Updated Phase II study results including progression-free survival (PFS). Accessed July 25, 2025. https:\/\/clin.larvol.com\/abstract-detail\/ESMO%202017\/17569340."},{"issue":"2","key":"1751_CR80","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.clinthera.2018.12.007","volume":"41","author":"H Cai","year":"2019","unstructured":"Cai H, Zhang L, Li N, et al. Cost-effectiveness of Osimertinib as first-line treatment and sequential therapy for EGFR mutation-positive non-small cell lung cancer in China. Clin Ther. 2019;41(2):280\u201390. https:\/\/doi.org\/10.1016\/j.clinthera.2018.12.007.","journal-title":"Clin Ther"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01751-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01751-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01751-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:50:16Z","timestamp":1781646616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01751-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1751"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01751-0","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}